Biomet Spinal Business Expansion Backs 15% Stock Gain In February
This article was originally published in The Gray Sheet
Biomet's rapidly expanding spinal business and accelerating reconstructive device revenues, coupled with a history of predictable earnings growth, helped the firm's stock advance 15.2% during a generally chilly February for device issues. The stock closed the month at $38.81, a gain of $5.12.
You may also be interested in...
Biomet's $90 mil. cash acquisition of privately-held Biolectron will add the SpinalPak non-invasive spinal stimulator to Biomet's existing orthopedic offerings and complement the firm's SpF implantable spinal fusion stimulation product, Biomet says.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.